Aktis Oncology to Present at Upcoming March Investor Conferences

Aktis Oncology (NASDAQ:AKTS) announced that President and CEO Matthew Roden, Ph.D., will present at two investor conferences in March 2026: TD Cowen on March 3 and Leerink Partners on March 9.

Rhea-AI Summary

Aktis Oncology (NASDAQ:AKTS) announced that President and CEO Matthew Roden, Ph.D., will present at two investor conferences in March 2026: TD Cowen on March 3 and Leerink Partners on March 9.

Live webcasts will be available via the company's Investors site and archived replays will remain for about 90 days after each conference.

Argus Feb 25 session

-2.50% close to close Open Argus

Details

News Market Reaction – AKTS

On Feb 25, the first trading day after this news, AKTS closed 2.50% below the previous close.

Data tracked by StockTitan Argus for the Feb 25 session.

Market Context

This announcement highlights Aktis Oncology’s planned visibility at two March healthcare investor co...

Analysis

This announcement highlights Aktis Oncology’s planned visibility at two March healthcare investor conferences, offering management a platform to discuss its targeted radiopharmaceutical pipeline and post-IPO trajectory. In light of recent IPO-related milestones and major shareholder disclosures, investors may focus on messaging around development priorities, capital deployment, and partnering strategy. Upcoming presentations and subsequent corporate updates will be important markers for tracking execution in 2026.

Key Figures

Share price: $19.43 Daily move: 2.8% Volume today: 297,406 shares +5 more

Share price

$19.43

Pre-news current price

Daily move

2.8%

Price change over prior 24h

Volume today

297,406 shares

Compared with 20-day average 245,098

52-week high

$29.16

52-week trading range high

52-week low

$0.033

52-week trading range low

Market cap

$1,042,708,823

Equity value before conference news

TD Cowen presentation

1:10 p.m. ET, March 3, 2026

TD Cowen 46th Annual Health Care Conference

Leerink presentation

1:40 p.m. ET, March 9, 2026

Leerink Partners Global Healthcare Conference

Historical Context

2 past events · Latest: Jan 13

2 events

1. Jan 13

   IPO closing

   24h Move

   -1.8%

   Upsized IPO closing with full underwriters’ option at $18.00 per share.

2. Jan 09

   IPO accolades

   24h Move

   +60115.1%

   Backer congratulates Aktis on IPO, highlighting funding, pipeline and Lilly deal.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

radiopharmaceuticals

1 terms

radiopharmaceuticals medical

"focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations"

Radiopharmaceuticals are medicines that carry tiny amounts of radioactive material to help doctors see or treat disease inside the body, acting like a tracer dye for imaging or a microscopic guided missile for targeted therapy. They matter to investors because their safety, regulatory approval, production complexity, short shelf life and hospital reimbursement determine how quickly they can reach patients and generate revenue, affecting a company’s sales potential and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026.

TD Cowen 46^th Annual Health Care Conference
Date & Time: Tuesday, March 3, 2026, at 1:10 p.m. ET
Location: Boston, MA

Leerink Partners Global Healthcare Conference
Date & Time: Monday, March 9, 2026, at 1:40 p.m. ET
Location: Miami, FL

A live webcast of the presentations may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.

About Aktis’ Radioconjugate Platform
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anti-cancer activity through high penetration, internalization and retention in cancer cells, while quickly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most-advanced program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline.

Media Contact:
Melone Communications, LLC
Liz Melone
617-256-6622
liz@melonecomm.com

Investor Contact:
Precision AQ
Alex Lobo
212-698-8802
alex.lobo@precisionaq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Aktis Oncology (AKTS) present at the TD Cowen 46th Annual Health Care Conference in March 2026?

Aktis Oncology will present at TD Cowen on Tuesday, March 3, 2026 at 1:10 p.m. ET. According to Aktis Oncology, Matthew Roden, Ph.D., will deliver the presentation in Boston and a live webcast will be available on the company's investor site.

What is the date and time for Aktis Oncology (AKTS) at the Leerink Partners Global Healthcare Conference in March 2026?

Aktis Oncology is scheduled to present Monday, March 9, 2026 at 1:40 p.m. ET. According to Aktis Oncology, the presentation will be held in Miami and streamed live through the Investors section of the company website.

How can investors watch the Aktis Oncology (AKTS) March 2026 conference presentations online?

Investors can watch via a live webcast on the Aktis Oncology Investors website during each presentation. According to Aktis Oncology, archived replays will be posted on the same site for approximately 90 days after the conferences.

Who will represent Aktis Oncology (AKTS) at the March 2026 investor conferences?

Matthew Roden, Ph.D., President and Chief Executive Officer, will present at both March 2026 conferences. According to Aktis Oncology, he will speak at TD Cowen on March 3 and at Leerink Partners on March 9.

Will Aktis Oncology (AKTS) provide archived replays of the March 2026 presentations and for how long?

Yes, archived replays will be available on the company's investor website for about 90 days. According to Aktis Oncology, replay access will follow each conference and remain posted for approximately 90 days.